In keeping with these findings, newly we showed that, upon doxorubicin treatment (Fig. 1), TG2 translocates into the nucleus and catalyzes the formation of covalent cross-linked IRF3 (Interferon regulatory factor 3) dimers, thereby limiting the production of IFNβ in dying melanoma cells [51]. This evidence concerns the gene IRF3 and melanoma.